Germline editing may be far from meeting legal standards in US
by Nic Zumaran | 25 Aug 2019 |
_640_362_c1_c_c.jpg)
Proposed trials in germline editing – the deliberate modification of genes passed on to children and future generations – would need to meet high legal standards before current bans are lifted in the US. This is highly unlikely, according to bioethicist Jennifer M. Gumer, of Columbia University. She argues in The Hastings Center blog that the risks presented by germline editing for a child-to-be are not outweighed by direct benefits.
Gumer’s analysis was prompted by a recent proposal from Russian scientist Denis Rebrikov to produce gene edited babies. He intends to be the second scientist to edit the human genome, after Chinese researcher He Jiankui.
The recent controversy over CRISPR prompted an informal moratorium on editing human germline cells (sperm, eggs, or embryos). Some claim, however, that CRISPR technology will eventually be safe enough for clinical use on the human germline.
But Gumer believes a proposed germline editing trial is unlikely to meet US legal standards. Germline editing would fall under gene therapy regulations set by the Food and Drug Administration (FDA). When research involves human embryos a Federal law prevents the FDA from approving it.
Gumer highlights Subpart D of the Common Rule. This indicates that research entailing more than a minimal risk must provide a prospect of direct benefit to the child. Minimal risk means that “the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests”. This sets the bar so high that germline editing is unlikely.
Gumer advances several reasons. First, CRISPR research involves relatively high frequencies of off-target edits (unintended edits to other genes) as well as unsuccessful editing attempts resulting in damaging effects. Second, our lack of understanding of the complexity of the human genome means there may be greater-than-minimal risks associated with germline editing. Finally, even assuming that the technical risks can be resolved, germline editing must be performed in conjunction with IVF, which already has its own risks.
Nic Zumaran writes from Sydney
Sorry, guys, late again. There's a good variety of topics below -- we'd love to get your comments.
 Michael Cook Editor BioEdge |  |  |  |
NEWS THIS WEEK
by Michael Cook | Aug 25, 2019
What happens when private interests trump public necessity?by Michael Cook | Aug 25, 2019
Some have been using their own sperm to get clients pregnantby Michael Cook | Aug 25, 2019
A wife’s devotion pays off by Michael Cook | Aug 25, 2019
If it works in mice, it could also work with humansby Nic Zumaran | Aug 25, 2019
The risks for a child-to-be are not outweighed by direct benefitsby Xavier Symons | Aug 25, 2019
And how should we understand the idea of 'the patient's good'?by Xavier Symons | Aug 24, 2019
Children are being abandoned by their commissioning parentsIN DEPTH THIS WEEK
by Patrick Foong | Aug 25, 2019
Amazingly, recent experiments fall between regulatory stools in Australiaby Anna Almendrala | Aug 24, 2019
Some argue that compulsory information pamphlets might make victims feel responsible for abuseBioEdge
Level 1, 488 Botany Road, Alexandria NSW 2015 Australia
Phone: +61 2 8005 8605
Mobile: 0422-691-615
No hay comentarios:
Publicar un comentario